why does nobody talk about cagrilintide
why does nobody talk about cagrilintide — that is what I am asking, and I have already read the wiki twice. The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised. Kept a log purely because so few people are logging this one. It is one…
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Small fix — amylin analogue, not a GLP-1 analogue.
freya_baptista is right that the evidence base here is thin. Conclusions should be held loosely.
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
nothing here is approved as a standalone product and research material is not for human use
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
Correction: that is the combination programme, not the monotherapy readout.
Agreed, and the combination arms are where the interesting numbers actually live.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes.
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
amylin analogue, different receptor family, different story
do not assume the dosing intuitions from the GLP-1 boards transfer